Featured Resources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
Integrated Drug Discovery
We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.
Integrated drug discovery brings every discipline needed to take a project from target identification to a pre-clinical candidate – chemistry, biology, structural biology, computational science, DMPK and in vivo pharmacology – into one co-located team working to a single plan, rather than a chain of separate vendors.
At Sygnature Discovery our teams work across the drug discovery process, from target identification through to candidate selection and pre-clinical development. With more than 700 experts from over 50 countries, and no internal drug pipeline, our sole focus is your success.
supporting your research
In drug discovery, collaboration is key, not only to the quality of the output, but to the speed of delivery.
At Sygnature Discovery, we don’t operate in silos. Our multidisciplinary teams work side by side in shared offices and laboratories, enabling real-time collaboration, transparency, and faster decision-making. Physical proximity eliminates delays, accelerates design-make-test-analyze (DMTA) cycles, and aligns disciplines, moving ideas quickly from data to decision. Our agile, integrated approach shortens feedback loops, enhances problem-solving and enables us to deliver high-quality candidates with speed and confidence.
Our Offering
We combine new talent and experienced pharmaceutical industry experts from around the world, with advanced technologies, to deliver excellence across every stage of discovery. We have 3 fully integrated drug discovery hubs in the UK and North America.
Target Identification & Validation
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Hit Identification
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Hit-to-Lead
High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.
Lead Optimization
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
our process
We tailor every integrated drug discovery program to your needs.
Our globally recruited scientists work within a transparent, collaborative framework supported by advanced informatics and a co-located infrastructure. Each program is led by a highly qualified and dedicated project leader with relevant drug discovery experience, ensuring strategic alignment and scientific rigor from start to finish. We deliver robust, decision-ready data, even for the most complex projects. Our teams are committed to working closely with you, sharing knowledge, solving problems, and driving progress together.
Our Approach
Drug discovery is evolving, and so are the challenges. As global health demands rise, the need for smarter, faster, and more connected science has never been greater. Yet too often, progress is slowed by disconnection between disciplines and data.
At Sygnature Discovery, our aim is to reshape how drug discovery is delivered. Through flexible services and integrated expertise, we enable innovation at every stage. With AI and automation embedded across our workflows, we help you move faster and make confident decisions, delivering high quality results with integrity.
Whether we’re supporting you through the entire process or just a part of it, our goal isn’t simply to move you to the next stage, it’s to lay the foundations for a successfully marketed drug.
Why Choose Sygnature for Integrated Drug Discovery?
Since 2011, Sygnature Discovery has delivered over 60 novel pre-clinical and 35+ clinical compounds, with our scientists named on over 200 patents. Our therapeutic areas of expertise span oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.
What sets Sygnature apart is our co-located, multidisciplinary setup, where chemists, biologists, DMPK experts, and in vivo pharmacologists work side by side in shared lab spaces. This physical proximity fosters real-time collaboration, transparency, and faster decision-making, eliminating delays. It enables tighter alignment across disciplines, accelerates DMTA cycles, and ensures that every project is focused on a collective drive towards the identification of a strong candidate.
It has been a pleasure to work with the Sygnature team on our best-in-class inhibitor project. From project start, the multidisciplinary team at Sygnature functioned as an extension of our in-house team, providing additional expertise across the drug discovery process; particularly in protein sciences, computational and synthetic chemistry and in vivo biology.
They responded fearlessly to our ambitious timelines and collaborated closely to allow us to achieve preclinical candidate compound nomination within a really impressive timeframe. I wouldn’t hesitate to work with the Sygnature team again.
Helen Harrison
Director of Discovery Biology, STORM Therapeutics
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Sitryx: Empowering New Ideas
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Corcept Therapeutics: Integrated Drug Discovery Collaboration
Corcept Therapeutics, located in Menlo Park, CA, is a leader in the discovery and development of drugs that regulate the effects of cortisol.
CellCentric Lead Optimisation Campaign – CCS1477
CellCentric are developing new treatments for cancer based on their understanding of epigenetics.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates
UK-based small molecule drug discovery company
Focus on identifying novel treatments of inflammatory respiratory diseases, such as COPD
Explore integrated drug discovery at Sygnature
Integrated drug discovery draws on every part of Sygnature. Browse the full picture:
Stages of the pipeline
Target Identification & Validation
Combining AI-driven insights, expert guidance, and rigorous lab validation to select and confirm targets for successful drug discovery.
Hit Identification
Delivering validated, high-quality hits through integrated technologies, strategic insight, and expert collaboration to advance your program with confidence.
Hit to Lead
Transforming promising hits into viable leads through tailored strategies, early risk assessment, and integrated expertise for clinical success.
Lead Optimisation
Transforming early leads into clinical-quality candidates through integrated expertise, rapid decision-making, and optimized strategies for safety, potency, and exposure.
Fragment Based Drug Discovery
From high -quality starting points to optimized leads, we unite fragment screening, structural biology, computational chemistry and medicinal chemistry to keep your program moving forward .
Scientific Solutions
Computer Aided Drug Design
Our Computer Aided Drug Design (CADD) capabilities combine deep scientific expertise with advanced AI, machine learning, and informatics infrastructure to support smarter, faster decision-making across the drug discovery pipeline.
Chemistry
Global chemistry expertise and tailored strategies combining medicinal, synthetic, and process capabilities advancing candidate-quality molecules with transparent collaboration.
Bioscience
Tailored bioscience solutions combining advanced technologies and collaborative expertise to design robust assays and accelerate confident drug discovery decisions.
Protein & Structure
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
DMPK
Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.
in vivo Pharmacology
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
Modalities and therapeutic areas
Modalities
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Therapeutic Areas
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Direct-to-Biology
Embedding Direct‑to‑Biology methodologies into customer programs enables rapid, systematic expansion of SAR. This approach shortens the path to lead optimization and accelerates the delivery of candidate‑quality compounds.